Transcranial Doppler, Hydroxyurea Use Low for Sickle Cell Anemia

THURSDAY, Sept. 22, 2022 (HealthDay News) -- For children with sickle cell anemia (SCA), transcranial Doppler (TCD) ultrasound screening and hydroxyurea therapy use remains low, according to research published in the Sept. 20 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Laura A. Schieve, Ph.D., from the CDC in Atlanta, and colleagues analyzed data from the IBM MarketScan Multi-State Medicaid Database and examined TCD screening and hydroxyurea use for 3,352 children and adolescents with SCA aged 2 to 16 years.

Originally published on consumer.healthday.com, part of the TownNews Content Exchange.

0
0
0
0
0

Recommended for you

Load comments